Summary We conducted a retrospective review of fatal bleomycin pulmonary toxicity in patients treated for germ cell tumours dunng 1991-95 at the Beatson Oncology Centre, Glasgow. Case notes of patients treated with bleomycin were reviewed with respect to cumulative bleomycin dose, renal impairment, exposure to supplemental oxygen, thoracic radiotherapy and age. A total of 194 patients underwent chemotherapy, of whom 180 received bleomycin-containing regimens. Five fatal cases of pulmonary toxicity were identified, an incidence of 2.8%. These cases were older than the remaining patients (P < 0.001), with a median age at diagnosis of 55 vs 33 years. 
GCT has been questioned.
The reported incidence of non-fatal BPT is dependent on the diagnostic criteria used. but appears to be 5-10%7. and fatal BPI has been reported to occur in approximately 2% of treated cases (Blum et al. 1973 : Haas et al. 1976 : Dalgleish et al 1984 : White and Stover. 1984 : Comis. 1992 ). Early clinical data correlated an increased BPT incidence w ith several nrisk factors'. These included increasing cumulative bleomycin dose. the presence of renal impairment. adjunctive thoracic radiotherapy. use of supplemental oxygen or age above 70. Experience in this unit has prompted us to examine the relevance of age in particular detail as we feel that an increasing, incidence of fatal BPT is evident at a younger age than the quoted threshold of 70 years. Our concern has been that the risk of fatal BPT might. in a subgroup of older patients. outw eigh the potential benefit of bleomvcin as part of the curative chemotherapy for GCT. The criteria used for diagnosis of BPT x-ary between studies and this is reflected by the xxide range in reported incidence of toxicitv. For the purposes of this retrospective study we 1  1  72  72  210  210  0  1  0  0  1   0  50-59   10  2  61-158  101   30-330   207  2  2  8  3  6  1  40-49   36  2  55-172  106  30-390  183  6  10  26  6  24   6  30-39   62  0  44-168  108   90-360  209  21  6  56  15  33  14   20-29  68  0  51-195  114   60-390  213  24  3  65  9  42   17   < 20  3  0  97-132  117  270-360  330  2  0  3  0 (HCG) . although raised at diaanosis. had initially dropped before increasina. AFP 1499 IU 1-1 (< 5). HCG 866 ILU 1-1 (< 2). Staging computerized tomography (CT) scan showed no evidence of macroscopic metastases. He receis-ed four cycles of BEP chemotherapy with a cumulatis e dose of 330 U of bleomycin (the final 30-U increment w~as w-ithheld because of the des elopment of toxicityv). The tumour markers returned to normal by the beginning of the second cycle. Near completion of chemotherapy he was noted to hase deseloped basal crepitations on chest examination. Chest radiograph (CXR) showed some patchy shadowing and CT scan confirmed interstitial disease bibaso-posteriorlv. Pulmonars function tests (PFTs) revealed a restrictis e lung defect and a decreased carbon monoxide diffusion capacity (DLCO). 57%c of that predicted. A clinical diagnosis of BPT was made and the patient started on steroids w ith some initial benefit.
Ts o months later he developed a further increase in breathlessness. despite continuing steroids. CXR showed increased intrapulmonars shadow-ing and PFT revealed a further decrease in DLCO to 52%/ of that predicted. Despite increased steroids the dyspnoea progressed. and serial CXR documented progressive fibrosis and des elopment of cavitating lesions. Progressive hypoxia desveloped requiring increasing use of supplemental oxygen. Deterioration continued and the patient died of respirators failure 10 weeks after chemotherapy had finished. Autopsy showed diffuse alsveolar damage and pulmonars fibrosis consistent w ith BPT: there w as no evidence of tumour.
British Joumal of Cancer (1998) Because of the large size of the residual mass and lack of definitive histology, he proceeded to resection of the mass and orchidectomy (2 months after the last bleomycin dose). This was a prolonged procedure of 9 h requiring both laparotomy and thoraco-abdominal incision.
There was an estimated 9.51 blood loss during the procedure, and two chest drains were left in situ at the conclusion of the operation. 
DISCUSSION
The first reports of BPT described an incidence of 5% among patients receiving total cumulative doses of bleomycin below 450 U (Blum et al, 1973) . For cumulative doses greater than 550 U the incidence of BPT increased to 17%, with an intermediate incidence of 13% for doses between 450 and 550 U. Fatal BPT occurred in less than 1% of patients at the lower dose but increased to above 10% for those who received over 550 U of bleomycin. The correlation of dose with toxicity was confirmed by Haas et al (1976) , who found that for patients experiencing BPT the mean cumulative dose of bleomycin administered was significandly greater than that received by patients not developing toxicity. Fatal BPT can occur below the 450 U threshold. and the onset of BPT has been reported at cumulative doses lower than 100 U (Wilson et al, 1982; McLeod et al, 1987) . Few patients receive cumulative doses above 360 U, and our present practice is to implement a ceiling of 270 U. The majority of our patients had been entered into current EORTC and/or MRC randomized trials over the study period. Within these trials. and for those patients not treated as part of a study protocol, bleomycin was given at a dose of 30 U either Fatal bleomycin toxicity in gern cell turnours 1065 as a 1-h intravenous infusion or as an intramuscular injection (for patients receiving outpatient treatment). In no case was bleomycin given as an intravenous bolus injection. The majority of protocols stipulated weekly doses of bleomycin (a total of 90 U per 3-week cycle), with a total of four cycles of treatment (i.e. a maximum of 360 U of bleomycin). The mean cumulative dose of bleomycin, in our patients, was lower than we expected from our current practice. but 43 of the patients reviewed had been treated on studies in the early 1990s that prescribed a single dose of 30 U of bleomycin with each cycle of chemotherapy, with a protocol ceiling dose of 120 U.
BPT has been reported in patients with renal impairnent at low cumulative bleomycin doses (Bennett et al, 1980; Dalgleish et al, 1984 : McLeod et al. 1987 Blayney et al, 1993) . The terminal halflife of bleomycin is 2-4 h. and 70% of the administered dose is excreted in the urine within the first 24 h. The half-life can be greatly increased in the presence of renal impairment, with an exponential rise in the half-life as the creatinine clearance decreases below 35 ml min-'. A bleomycin half-life of 21 h has been reported in a patient with a creatinine clearance of only 10.7 ml min-' (Crooke et al, 1977) . Dose reduction is suggested for patients with creatinine clearances below 35 ml min-'; however, the development of BPT has been noted in cases with lesser degrees of renal impairment in the absence of other risk factors (Dalgleish et al, 1984) . The GFR of our fatal group was significantly lower than that of the non-fatal group, although there were comparable levels of renal impairment within the non-fatal group.
No patient had a dose reduction on the basis of their GFR, as the values were within acceptable treatment limits. Goldiner et al (1978) reported five fatal cases of BPT in patients post surgery. The onset of BPT after surgery was rapid, although the most recent administration of bleomycin in these patients had been 6-12 months previously. Goldiner et al postulated that the onset of BPIT in these patients was related to the use of high inspired oxygen concentrations of 34-40% during surgery, and extensive fluid replacement (blood loss was often 10-15 units) during the 6-to 8-h operation. When the inspired oxygen concentration was kept between 22% and 24%. and fluid status was closely monitored with Swan-Ganz catheterization during operation. there were no further cases of BPT in patients undergoing similar procedures. The potentiation of BPT by high inspired oxygen concentration has been supported by animal studies (Tryka et al. 1984) . In this review we have used surgery during or after chemotherapy as a surrogate measure of exposure to supplemental inspired oxygen before the development of BPT. as it was only during operations that the patients were exposed to supplemental oxygen according to clinical circumstances, although attempts were generally made to keep it low. There was no difference between the two groups in the frequency of operations performed.
and therefore there was no discernible effect of supplemental oxygen on the frequency of fatal BPT.
The fifth fatal case received teatment with GCSF because of grade HI prolonged neutropenia complicated by fever, during one cycle of chemotherapy. The possibility of synergy between bleomycin and GCSF in the aetiology of BPT has been raised (Matthews, 1993; Dirix et al, 1994) but has been refuted. In a large MRCIEORTC trial in which 263 patients receiving BEP or BOP/VIP chemotherapy for testicular teratoma were randomized either to receive GCSF or not, there was no evidence of an increase in BPT in the GCSF arm (Fossa et al, 1995) .
All five fatal cases reviewed were over the age of 40. although only 47 of the 180 patients treated with bleomycin were in this age group. Blum et al (1973) reported a BPT incidence of 2-6% for each decade of life, which increased dramatically to 15% for those patients over 70 years (interestingly six of the seven deaths reported in his paper occurred in patients over age 40). The risk of developing fatal pulmonary toxicity is related to age, but we are concerned that the threshold of accelerating risk is below that traditionally quoted of 70 years (Blum et al. 1973 : Haas et al. 1976 . and that this threshold may be apparent in the fifth decade of life. The role of bleomycin, as part of curative treatment, in this subgroup of patients needs to be consideredOur current standard therapy for good-prognosis GCT is four cycles of BEP chemotherapy. Einhom et al (1989) reported that for the treatment of favourable prognosis GCT, three cycles of BEP chemotherapy were as effective as four. Decreasing the total administered dose of bleomycin (as well as that of cisplatin and etoposide) by omitting the fourth cycle did not compromise patient outcome, and was also associated with less treatment toxicity. This observation is cufrently being tested in a large prospective randomized MRC/EORTC trial (three vs four courses of BEP chemotherapy), although in this trial bleomycin is omitted from the fourth course of BEP (effectively a course of cisplatin and etoposide chemotherapy) in order to ensure an equal total dose of bleomycin (270 U) in both teatment arms.
A review of the literature indicates that four randomized trials have been performed assessing whether bleomycin could be withheld from standard regimens to lessen toxicity without compromising clinical response. The weight of evidence from these studies (Table 3) suggests that disease-free survival (DFS) of patients with good-prognosis disease decreases if bleomycin is omitted from these chemotherapy regimens. This is apparent with the individual trials showing either decreased initial response or an increased relapse rate if bleomycin is not used. The ECOG trial (Loehrer et al, 1995) . which employed only three cycles of chemotherapy, showed the largest increase in relapse rate as a result of omitting bleomycin, and the trial was closed as a result of an interim analysis. In many centres this has led to the adoption of a policy of treating with three cycles of BEP as routine, or with four cycles of EP if bleomycin is contra-indicated. The EORTC trial (De Wit et al, 1997) . the largest individual trial, shows a statistically significant decrease from 95% to 87% in attaining a disease-free state is bleomycin is withheld from primary chemotherapy, but only a 4% difference in DFS. and no significant difference in the overall survival of treated patients. This trend is supported by the other studies, although does not reach statistical significance, perhaps because of their smaller size. Most of the trials report similar relapse rates between their two treatment arms. The trial from the Memorial Sloan-Kettering Cancer Centre (Bosl et al. 1988) shows no significant difference in outcome between the two treatment arms. but the combinations being compared differed in other respects as well as the omission of bleomycin. hence the results are not directly comparable with the other trials.
Three of these four trials included both patients with seminoma or NSGCT in their analyses. although the numbers treated for seminoma were small. Previous studies have found cisplatin and etoposide chemotherapy to be highly effective treatment for advanced seminoma with a DFS of about 90% (Mencel et al. 1994) . but the benefit of adding bleomycin to cisplatin and etoposide for this subgroup of GCT has not been studied. The peak age British Journal of Carcer (1998) 78(8), 1061-1066 0 Cancer Researd7 Campaign 1998 incidence of seminoma is substantially different from that of NSGCT. 35-39 years vs 25-29 years respectively (Forman and Moller. 1994) . and therefore is more prevalent among the older GCT patients. i.e. the subgroup of patients that we feel are at greater risk of developing fatal BPT.
In our view. for that group of patients with GCT over 40 years of age. particularly those with a GFR at the lower end of the normal range. it is preferable to accept the possibility of a reduction in DFS by perhaps 4% in order to avoid a risk of fatal BPT that may exceed 10%. We have therefore discontinued the routine use of bleomycin in these patients. with good prognosis disease. for whom our standard regimen comprises four cycles of treatment with cisplatin and etoposide.
